Related video above: Moderna working to have COVID-19 vaccines for children as young as 5 by early fallModerna has released its latest findings from a third-phase study of patients receiving its COVID-19 vaccine.According to a release from the company, the data shows 93% efficacy six months after the second dose. The Massachusetts-based company also said a study in its second phase "induced robust antibody responses" against the gamma, beta and delta variants of COVID-19 for three booster candidates. The company has submitted this data to a peer-reviewed journal for publication. The company also has ongoing efficacy studies for adolescents aged 12 to 17 and for pediatric patients age 6 months to 11 years old.

A fourth vaccine is getting closer to a meeting with the FDA to ask for emergency approval as vaccine clinics expand and supplies of other vaccines remain tight.AstraZenica is analyzing the date collected in the U.S. and will take their findings to the FDA soon.“Within a month, maybe sooner than that,” said Dr. Robert Frenck.Frenck is a researcher at Cincinnati Children’s Hospital. He led the research here on the Pfizer vaccine and worked on AstraZenica study more recently.“They have to do the analysis. They have to have enough cases to say what the efficacy was but, assuming there’s a positive there, they would be submitting the information to the FDA,” Frenck said.AstraZenica said results from studies in the UK, Brazil and South Africa have shown its vaccine is 100 percent effective against severe cases and hospitalizations. Overall effectiveness is 82 percent after two doses.The U.S. results have not been made public yet.AstraZenica emerges as concerns about variants continue to grow.“The good news is that the vaccines have shown good efficacy against the variants so far. The other thing is that these platforms, the AstraZenica, the Johnson and Johnson, as well as the MRNA vaccines are ones that can be tweaked, really very quickly,” Frenck said.